• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature.

作者信息

Deinlein Teresa, Lax Sigurd F, Schwarz Thomas, Giuffrida Roberta, Schmid-Zalaudek Karin, Zalaudek Iris

机构信息

Department of Dermatology, Medical University of Graz, Graz, Austria.

Department of Pathology, Hospital Graz South-West, Graz, Austria.

出版信息

Eur J Cancer. 2017 Sep;83:99-102. doi: 10.1016/j.ejca.2017.06.022. Epub 2017 Jul 19.

DOI:10.1016/j.ejca.2017.06.022
PMID:28734147
Abstract
摘要

相似文献

1
Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature.一名着色性干皮病患者的转移性皮肤鳞状细胞癌对派姆单抗的快速反应：病例报告及文献复习
Eur J Cancer. 2017 Sep;83:99-102. doi: 10.1016/j.ejca.2017.06.022. Epub 2017 Jul 19.
2
Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.帕博利珠单抗（PD1抗体）使着色性干皮病中的黑色素瘤转移灶及多种非黑色素瘤皮肤癌消退。
Eur J Cancer. 2017 May;77:84-87. doi: 10.1016/j.ejca.2017.02.026. Epub 2017 Mar 31.
3
Efficacy of pembrolizumab in a patient with xeroderma pigmentosum variant and advanced cutaneous squamous-cell carcinoma.帕博利珠单抗治疗一名着色性干皮病变异型及晚期皮肤鳞状细胞癌患者的疗效
Acta Oncol. 2022 Sep;61(9):1140-1142. doi: 10.1080/0284186X.2022.2109425. Epub 2022 Aug 11.
4
Clinical remission of xeroderma pigmentosum-associated squamous cell carcinoma with isotretinoin and chemotherapy: case report.
J Chemother. 1999 Aug;11(4):313-7. doi: 10.1179/joc.1999.11.4.313.
5
Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum.着色性干皮病中皮肤鳞状细胞癌预防的免疫治疗策略。
Br J Dermatol. 2019 Nov;181(5):1095-1097. doi: 10.1111/bjd.18144. Epub 2019 Aug 7.
6
Dramatic response to nivolumab in xeroderma pigmentosum skin tumor.色素性干皮病皮肤肿瘤对纳武单抗有显著反应。
Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26837. Epub 2017 Oct 8.
7
A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.一例对程序性细胞死亡蛋白1抑制剂帕博利珠单抗敏感的不可切除皮肤鳞状细胞癌病例报告
JAMA Dermatol. 2016 Jan;152(1):106-8. doi: 10.1001/jamadermatol.2015.2705.
8
Xeroderma pigmentosum: neck lymph node metastasis of a squamous cell carcinoma of the skin treated with cetuximab.着色性干皮病：西妥昔单抗治疗皮肤鳞状细胞癌颈部淋巴结转移
Eur J Dermatol. 2009 Mar-Apr;19(2):163-5. doi: 10.1684/ejd.2008.0574. Epub 2008 Dec 23.
9
Patterns of response and acquired resistance to the programmed death-1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma.III期转移性皮肤鳞状细胞癌对程序性死亡-1抑制剂帕博利珠单抗的反应模式及获得性耐药
Dermatol Ther. 2019 Nov;32(6):e13107. doi: 10.1111/dth.13107. Epub 2019 Oct 21.
10
Comparison of the clinical and histological effects of 5-fluorouracil (5-FU) alone and of 5-FU preceded by dimethyl-sulphoxide (DMSO) on senile keratosis.
Dermatologica. 1970;140:Suppl 1:119+. doi: 10.1159/000252605.

引用本文的文献

1
Case report: Neoadjuvant-intent pembrolizumab resulted in complete response in a xeroderma pigmentosum patient with locally advanced resectable cutaneous squamous cell carcinoma of the nose.病例报告：新辅助治疗目的的帕博利珠单抗使一名患有局部晚期可切除鼻部皮肤鳞状细胞癌的着色性干皮病患者获得完全缓解。
Front Med (Lausanne). 2024 Oct 11;11:1488400. doi: 10.3389/fmed.2024.1488400. eCollection 2024.
2
Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers.22例患有转移性或不可切除癌症的着色性干皮病患者使用免疫检查点抑制剂的疗效和不良事件的回顾性研究。
Front Oncol. 2023 Oct 25;13:1282823. doi: 10.3389/fonc.2023.1282823. eCollection 2023.
3
Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum?西米普利单抗能否成为色素性干皮病的改变命运之药？
Dermatol Pract Concept. 2023 Jul 1;13(3):e2023160. doi: 10.5826/dpc.1303a160.
4
Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma.淋巴结清扫术治疗皮肤鳞状细胞癌的肿瘤学结果。
Ann Surg Oncol. 2023 Aug;30(8):5017-5026. doi: 10.1245/s10434-023-13306-9. Epub 2023 Mar 29.
5
Homozygous CRISPR/Cas9 Knockout Generated a Novel Functionally Active Exon 1 Skipping XPA Variant in Melanoma Cells.同源 CRISPR/Cas9 基因敲除在黑色素瘤细胞中产生一种新型功能活跃的外显子 1 跳跃 XPA 变异体。
Int J Mol Sci. 2022 Oct 1;23(19):11649. doi: 10.3390/ijms231911649.
6
Relationship between PD-L1 expression and prognostic factors in high-risk cutaneous squamous and basal cell carcinoma.PD-L1 表达与高危皮肤鳞状细胞癌和基底细胞癌预后因素的关系。
Bosn J Basic Med Sci. 2022 Oct 23;22(6):894-900. doi: 10.17305/bjbms.2022.7574.
7
Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response.非黑色素瘤皮肤癌患者中免疫治疗候选者的识别：反应潜在预测因素综述
J Clin Med. 2022 Jun 11;11(12):3364. doi: 10.3390/jcm11123364.
8
Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients.可溶性CTLA-4、PD-1、PD-L1、LAG-3和TIM-3水平升高以及全身炎症应激可能是南非着色性干皮病患者队列中免疫抑制和全身性肿瘤发生的潜在因素。
Front Oncol. 2022 Feb 11;12:819790. doi: 10.3389/fonc.2022.819790. eCollection 2022.
9
The Prognostic and Predictive Role of Xeroderma Pigmentosum Gene Expression in Melanoma.着色性干皮病基因表达在黑色素瘤中的预后和预测作用
Front Oncol. 2022 Jan 31;12:810058. doi: 10.3389/fonc.2022.810058. eCollection 2022.
10
Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review.着色性干皮病的免疫治疗：1例用西米普利单抗治疗的晚期皮肤鳞状细胞癌病例及文献综述
Oncotarget. 2021 May 25;12(11):1116-1121. doi: 10.18632/oncotarget.27966.